Fig. 4.

Candesartan elicits an antiangiogenic effect in prostate cancer xenografts in mice. Treatment of nude mice with clinically relevant doses of candesartan reduced vascular density via inhibition of VEGF expression. (A) Representative fluorescent images of tumor xenograft sections showing laminin positive blood vessels as indicated by arrows. (B) Bar graph showing reduced vascular area in tumor xenografts treated with clinically relevant doses of candesartan as compared with saline-treated controls. Representative Western blot (C) and bar graph (D) showing reduced expression of VEGF in tumor xenografts treated with clinically relevant doses of candesartan as compared with saline-treated controls. (E) Representative Western blot (bottom) and bar graph (top) showing a dose-dependent inhibition of VEGF expression in PC3 tumor cells treated with clinically relevant doses of candesartan as compared with vehicle-treated controls. Data are presented as the mean ± S.D. OD, optical density.